Sintilimab improves survival in advanced gastric, gastroesophageal junction cancer

Adding sintilimab to chemotherapy improved survival compared with placebo among patients with unresectable locally advanced or metastatic gastric and gastroesophageal junction adenocarcinoma, phase 3 study results published in JAMA showed.
The strongest survival benefit appeared to be among the subset of patients with a PD-L1 combined positive score of 5 or greater, according to researchers.
“Among patients with previously untreated advanced gastric or gastroesophageal junction adenocarcinoma, adding sintilimab to standard chemotherapy was associated with significantly improved overall

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart